Neil Berkley serves as Alector’s Chief Financial Officer and Chief Business Officer, having joined Alector in 2024.
Neil brings over twenty years of experience in corporate development, business development, and strategic planning from large pharma, midsize biotech/pharma, and small biotech companies. Prior to joining Alector, Neil was Chief Corporate Development Officer at Juvena Therapeutics, a Series A start-up biotech focused on metabolic and muscle diseases, Chief Business Officer at AbCellera, a public biotech company focused on discovering novel antibody therapeutics, and Vice President and Head of Business Development at Halozyme Therapeutics, a public biotech focused on enabling drug delivery platforms. Neil has also held various business development and corporate development roles at Axerovision, COI (Avalon Incubator), Acadia, and GSK. Earlier in his career, Neil was Head of Business Development at Cadence Pharmaceuticals, where he assisted with the sale of the company for $1.3B. Neil also co founded and helped build two San Diego-based biotech companies, Mpex Pharmaceuticals (acquired by Aptalis) and Vaxiion.
Neil holds a B.S. in Molecular Biology from UC San Diego, as well as an M.S. in Cellular and Molecular Biology and an M.B.A. from San Diego State University.
What is Neil Lindsay Berkley's net worth?
The estimated net worth of Neil Lindsay Berkley is at least $567.95 thousand as of June 2nd, 2026. Berkley owns 379,900 shares of Alector stock worth more than $567,951 as of July 31st. This net worth approximation does not reflect any other investments that Berkley may own. Learn More about Neil Lindsay Berkley's net worth.
How do I contact Neil Lindsay Berkley?
Has Neil Lindsay Berkley been buying or selling shares of Alector?
Neil Lindsay Berkley has not been actively trading shares of Alector during the past quarter. Most recently, Neil Lindsay Berkley sold 19,360 shares of the business's stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $1.97, for a transaction totalling $38,139.20. Following the completion of the sale, the chief financial officer now directly owns 379,900 shares of the company's stock, valued at $748,403. Learn More on Neil Lindsay Berkley's trading history.
Who are Alector's active insiders?
Are insiders buying or selling shares of Alector?
During the last year, insiders at the sold shares 14 times. They sold a total of 338,673 shares worth more than $513,284.20. The most recent insider tranaction occured on June, 3rd when insider Grace Wong-Sarad sold 3,475 shares worth more than $6,533.00. Insiders at Alector own 8.3% of the company.
Learn More about insider trades at Alector. Information on this page was last updated on 6/3/2026.
